Corcept Therapeutics (CORT)
107.50
-8.78 (7.55%)
Upcoming Events
Latest Headlines
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
October 20, 2026 4:00 PM - BizWire
Corcept Therapeutics (CORT) spreader of 2500 contracts of January 120 and 160 calls
October 20, 2026 2:32 PM - StreetInsider
Form 4 CORCEPT THERAPEUTICS For: Oct 15 Filed by: WILSON JAMES N
October 16, 2026 6:25 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Oct 02 Filed by: Vieira Roberto Wandenkolk
October 5, 2026 7:59 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Lyon Joseph Douglas
October 5, 2026 7:54 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Maduck Sean
October 5, 2026 7:49 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Gunn Justin Frederick
October 5, 2026 7:45 PM - SEC Filing
Form 3 CORCEPT THERAPEUTICS For: Oct 01 Filed by: Gunn Justin Frederick
October 5, 2026 7:18 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Lyon Joseph Douglas
October 1, 2026 11:09 AM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Sep 24 Filed by: Robb Gary Charles
September 28, 2026 4:30 PM - SEC Filing
Form 8-K CORCEPT THERAPEUTICS For: Sep 22
September 23, 2026 8:15 AM - SEC Filing
Corcept names Justin Gunn president of endocrinology division
September 23, 2026 8:04 AM - StreetInsider
Corcept Announces Planned Leadership Transition
September 23, 2026 8:00 AM - BizWire
Form 4 CORCEPT THERAPEUTICS For: Sep 16 Filed by: Vieira Roberto Wandenkolk
September 18, 2026 7:54 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Sep 17 Filed by: Robb Gary Charles
September 18, 2026 7:48 PM - SEC Filing
EU panel recommends approval of Corcept's relacorilant for ovarian cancer
September 18, 2026 8:00 AM - StreetInsider
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
September 18, 2026 8:00 AM - BizWire
Form 4 CORCEPT THERAPEUTICS For: Sep 14 Filed by: Lyon Joseph Douglas
September 16, 2026 4:31 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Sep 15 Filed by: WILSON JAMES N
September 16, 2026 4:30 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: WILSON JAMES N
September 15, 2026 10:24 AM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Lyon Joseph Douglas
September 14, 2026 1:59 PM - SEC Filing
S&P announces major changes in S&P 100, S&P 500, S&P 400
September 4, 2026 5:32 PM - StreetInsider
S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
September 4, 2026 5:17 PM - StreetInsider
Form 4 CORCEPT THERAPEUTICS For: Aug 26 Filed by: Park Kimberly
August 28, 2026 4:31 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 25 Filed by: Maduck Sean
August 27, 2026 4:30 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Park Kimberly
August 26, 2026 4:15 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Maduck Sean
August 25, 2026 5:25 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 18 Filed by: MAHONEY DAVID L
August 20, 2026 4:30 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 14 Filed by: WILSON JAMES N
August 18, 2026 4:30 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 14 Filed by: Maduck Sean
August 18, 2026 4:30 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 17 Filed by: Robb Gary Charles
August 18, 2026 4:30 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: MAHONEY DAVID L
August 18, 2026 10:12 AM - SEC Filing
Truist Securities Assumes Corcept Therapeutics (CORT) at Buy
August 18, 2026 5:07 AM - StreetInsider
Form 144 CORCEPT THERAPEUTICS Filed by: Robb Gary Charles
August 17, 2026 4:06 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 12 Filed by: Robb Gary Charles
August 14, 2026 4:36 PM - SEC Filing
Form SCHEDULE 13G/A CORCEPT THERAPEUTICS Filed by: RENAISSANCE TECHNOLOGIES LLC
August 13, 2026 4:21 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 10 Filed by: Maduck Sean
August 12, 2026 4:28 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 10 Filed by: Guyer William
August 12, 2026 4:26 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 04 Filed by: Guyer William
August 12, 2026 11:03 AM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 04 Filed by: Guyer William
August 6, 2026 6:45 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 03 Filed by: Maduck Sean
August 5, 2026 5:51 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Aug 03 Filed by: Lyon Joseph Douglas
August 5, 2026 5:49 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Guyer William
August 4, 2026 3:07 PM - SEC Filing
Form 4 CORCEPT THERAPEUTICS For: Jul 30 Filed by: Mokari Atabak
August 3, 2026 4:31 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Lyon Joseph Douglas
August 3, 2026 12:17 PM - SEC Filing
Form 144 CORCEPT THERAPEUTICS Filed by: Mokari Atabak
July 30, 2026 4:04 PM - SEC Filing
Corcept Therapeutics (CORT) PT Raised to $165 at Piper Sandler
July 30, 2026 7:09 AM - StreetInsider
Corcept Therapeutics (CORT) PT Raised to $165 at H.C. Wainwright
July 30, 2026 6:45 AM - StreetInsider
Corcept Therapeutics (CORT) Tops Q2 EPS by 35c ; Offers Guidance
July 30, 2026 1:48 AM - StreetInsider
Form 10-Q CORCEPT THERAPEUTICS For: Jun 30
July 29, 2026 4:10 PM - SEC Filing
Form 8-K CORCEPT THERAPEUTICS For: Jul 29
July 29, 2026 4:08 PM - SEC Filing
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2026 4:05 PM - BizWire
Corcept Therapeutics (CORT) PT Raised to $150 at Canaccord
July 29, 2026 6:42 AM - StreetInsider
Corcept Therapeutics (CORT) call put ratio 1.4 calls to 1 put as share price up 5.2%
July 27, 2026 2:43 PM - StreetInsider
Wolfe Research Downgrades Corcept Therapeutics (CORT) to Underperform
July 27, 2026 1:22 AM - StreetInsider
Full Article List
